All lobbying filings

Daiichi Sankyo, Inc.

Daiichi Sankyo, Inc. filed a Q2 report for Daiichi Sankyo Inc. on July 19, 2026.

Lobbying for Daiichi Sankyo Inc.

As filed: DAIICHI SANKYO, INC. for DAIICHI SANKYO INC.

All filings by Daiichi Sankyo, Inc. · Everything Daiichi Sankyo Inc. has reported

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 19, 2026

Expenses

$380,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Lobbyists on this filing 1

COURTNEY VEATCH New on this filing

Previously held: DHS Counsel/Policy 2020-2021;Legislative Counsel, US House 2017-2020

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 4

Health Issues

Discussions regarding H.R.946, the ORPHAN Cures Act Discussions related to H.R.2319, the Women and Lung Cancer Research and Preventative Services Act Discussions related to the Protecting Patient Access to Cancer and Complex Therapies Act reintroduction Issues related to most-favored-nation and other foreign reference drug pricing policy Issues related to the Food and Drug Administration Issues regarding 340B program

Taxation/Internal Revenue Code

Discussions regarding tax reform and tariffs

Medicare/Medicaid

Issues related to the Medicare Drug Price Negotiation Program Issues regarding the GLOBE model

Issues related to intellectual property rights

Bills named in this filing 2

H.R. 946
ORPHAN Cures Act
H.R. 2319
Women and Lung Cancer Research and Preventive Services Act of 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.